Pomalyst is owned by Celgene.
Pomalyst contains Pomalidomide.
Pomalyst has a total of 12 drug patents out of which 0 drug patents have expired.
Pomalyst was authorised for market use on 08 February, 2013.
Pomalyst is available in capsule;oral dosage forms.
Pomalyst can be used as use of pomalidomide with dexamethasone for patients with multiple myeloma after at least two prior therapies including lenalidomide and a proteasome inhibitor and demonstrated disease progression on or within 60 days of completing the last therapy; use of pomalidomide for the treatment of multiple myeloma, use of pomalidomide for the treatment of multiple myeloma; use of pomalidomide with dexamethasone for patients with multiple myeloma after at least two prior therapies including lenalidomide and a proteasome inhibitor and demonstrated disease progression on or within 60 days of completing the last therapy.
The generics of Pomalyst are possible to be released after 21 December, 2031.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8828427 | CELGENE | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
Jun, 2031
(8 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8673939 | CELGENE | Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
May, 2023
(a month from now) | |
US8735428 | CELGENE | Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
May, 2023
(a month from now) | |
US8735428
(Pediatric) | CELGENE | Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
Nov, 2023
(7 months from now) | |
US8673939
(Pediatric) | CELGENE | Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
Nov, 2023
(7 months from now) | |
US8198262 | CELGENE | Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
Jun, 2025
(2 years from now) | |
US8198262
(Pediatric) | CELGENE | Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
Dec, 2025
(2 years from now) | |
US9993467 | CELGENE | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
May, 2030
(7 years from now) | |
US10555939 | CELGENE | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
May, 2030
(7 years from now) | |
US9993467
(Pediatric) | CELGENE | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
Nov, 2030
(7 years from now) | |
US10555939
(Pediatric) | CELGENE | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
Nov, 2030
(7 years from now) | |
US8828427
(Pediatric) | CELGENE | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
Dec, 2031
(8 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
M (M) | Nov 20, 2023 |
Orphan Drug Exclusivity (ODE) | May 14, 2027 |
Pediatric Exclusivity (PED) | May 20, 2024 |
Drugs and Companies using POMALIDOMIDE ingredient
Market Authorisation Date: 08 February, 2013
Treatment: Use of pomalidomide for the treatment of multiple myeloma; Use of pomalidomide with dexamethasone for patients with multiple myeloma after at least two prior therapies including lenalidomide and a proteasome inhibitor and demonstrated disease progression on or within 60 days of completing the last therapy
Dosage: CAPSULE;ORAL
97
United States
29
China
28
Canada
27
European Union
24
Japan
14
New Zealand
14
Korea, Republic of
14
Australia
13
Mexico
10
Israel
9
Portugal
9
Spain
9
Hong Kong
9
Denmark
8
South Africa
7
Poland
6
Brazil
6
Norway
6
Taiwan, Province of China
6
Slovenia
5
Costa Rica
5
Cyprus
5
Hungary
4
Russia
4
Ukraine
3
Croatia
3
Argentina
3
Peru
3
ME
3
Ecuador
2
Austria
2
Lithuania
2
Iceland
2
RS
1
Turkey
1
Germany
1
Singapore
1
San Marino
1
Colombia
1
AP
1
Philippines
1
Morocco
1
EA
1
Nicaragua
1
Luxembourg
1
Yugoslavia
1
OA
1
Georgia
1
Chile
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic